Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Calculating the fatal dose of novel psychoactive substances

The article ‘Have legislative changes curbed use of ’legal highs’?’ (The Pharmaceutical Journal 2018;301:7920) concerning novel psychoactive substances (NPSs) highlighted the huge number of these drugs that are now available, with more appearing each week. One problem is that many of these NPSs have very limited or no data on which to base assessments of their toxicity.

I have recently found, using a quantitative toxicity–toxicity relationship (QTTR) approach, that the human fatal dose (HFD) of psychoactive drugs correlates very well with their rat and mouse intravenous LD50 (amount of an ingested substance that kills 50% of the test sample) values. For a diverse series of 18 psychoactive drugs taken from Gable[1], the human–rat correlation had r2 = 0.823, s = 0.473, while the human–mouse correlation had r2 = 0.756, s = 0.541 (r2 is coefficient of determination; s is standard error of prediction (log units)). For three external test drugs, predicted HFD values were all within one standard deviation of the observed values.

Two software packages, TerraBase and ACD/Labs, predict rodent LD50 values, and these also correlate well with HFD values (human–rat r2 = 0.654, s = 0.644; human–mouse r2 = 0.678, s = 0.621). While these correlations are not as good as those using experimentally-measured rodent LD50 values, they nevertheless yielded predicted HFD values within one standard deviation of the observed values.

Hence, the use of measured or calculated rodent LD50 values can rapidly give an indication of the likely HFD of a new psychoactive drug, provided that it is of the same chemical and activity class as one or more of the 18 drugs used to develop the QTTR. A paper describing this work has been accepted for publication in the International Journal of Quantitative Structure-Property Relationships, and will be published in early 2019.

John Dearden, emeritus professor of medicinal chemistry, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20205940

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.